Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?
- Published In:
- Neuropharmacology, 253, 109952 (2024)
- Authors:
- Hölscher, Christian(6)
- Database ID:
- RPEP-08424
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-08424APA
Hölscher, Christian. (2024). Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?. Neuropharmacology, 253, 109952. https://doi.org/10.1016/j.neuropharm.2024.109952
MLA
Hölscher, Christian. "Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?." Neuropharmacology, 2024. https://doi.org/10.1016/j.neuropharm.2024.109952
RethinkPeptides
RethinkPeptides Research Database. "Glucagon-like peptide-1 class drugs show clear protective ef..." RPEP-08424. Retrieved from https://rethinkpeptides.com/research/holscher-2024-glucagonlike-peptide1-class-drugs
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.